Drug Users With Hepatitis C Virus Can Achieve a Sustained
View PDF | Print View
by: Guest
Total views: 123
Word Count: 411
DGDispatch
Drug Users With Hepatitis C Virus Can Achieve a Sustained Virologic Response With Standard Treatment: Presented at AASLD
By Maria Bishop
BOSTON, MA -- November 5, 2007 -- Current and former illicit drug users who have hepatitis C virus (HCV) are able to achieve a sustained virologic response (SVR) with standard treatment, according to research presented here at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
In developed nations, intravenous drug users (IDUs) account for over 50% of prevalent and over 75% of incident HCV infection, noted Jason Grebely, PhD, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. In many centres, it is recommended that IDUs not receive HCV treatment on the basis that adherence, psychological side effects, and re-infection may pose barriers to treatment.
Dr. Grebely led a team of colleagues in an open-label, prospective observational trial of 51 non-cirrhotic subjects with HCV who were current or former illicit drug users for whom HCV treatment was initiated.
SVR.
Illicit drugs were used by 21 of the 51 subjects (41%) in the 6 months preceding therapy, and by 29 of 51 (57%) during treatment.
Following SVR, 28 subjects were followed for a mean of 1.1 years (range, 0 to 3.2 years). In this period, 13 of the 28 patients (46%) reported using illicit drugs (3: injection heroin/cocaine and crack cocaine, 2: injection heroin and crack cocaine, 1: injection cocaine and crack cocaine, 3: injection cocaine, 2: injection heroin, 2: crack cocaine).
At the outset of this study, all subjects had a reasonable expectation of adherence to therapy. Subjects attended the clinic weekly. Ribavirin was self-administrated, while interferon alfa 2b and pegylated interferon alfa 2a or 2b were administered by nurses as direct observed therapy.
Dr. Grebely concluded that there is certainly a rationale for expanding treatment in this group, but that research is required to understand whether the success in this population is associated with protective immunity against HCV re-infection or reduced risk behaviors for acquisition following successful treatment.
This study was supported by the National Canadian Research Training Program in Hepatitis C, the Canadian Institutes for Health Research, Vancouver Coastal Health and the Vancouver Foundation.
Presentation title: Infrequent Hepatitis C Virus (HCV) Re-infection after Sustained Virological Response (SVR) Among Current and Former Injection Drug Users (IDUs) Having Received Treatment for HCV Infection.
Related: Drug Users With Hepatitis C Virus Can Achieve a Sustained
Additional information:
From www.docguide.com:
Brady, an assistant professor in the Division of Pediatric Critical Care and Anesthesiology, received the award for his work on a monitor.
One of the largest residency training programs in the country, with more than 70 faculty anesthesiologists overseeing nine centers.
Publishes short condensations of the most significant articles.
Anesthesiology Online is an online informational and educational resource for anesthesia.
News on Anesthesiology continually updated from thousands of sources.
Examines and certifies physicians who complete an accredited program of anesthesiology training in the United States and voluntarily.
Clinical teaching with basic and clinical research in the areas of anesthetic mechanisms, critical care and pain management.
Contains membership information and resources, patient information, meeting information, continuing education.
Rating:
Not yet rated
Comments
No comments posted.
Add Comment
You do not have permission to comment. If you
log in, you may be able to comment.
